Literature DB >> 12559880

Primary brain tumours in adults.

Anthony Behin1, Khe Hoang-Xuan, Antoine F Carpentier, Jean-Yves Delattre.   

Abstract

The most frequent primary brain tumours in adults are gliomas and primary CNS lymphomas. In gliomas, molecular genetic analysis plays an increasing part in classification and treatment planning, a feature well illustrated by the chemosensitive oligodendrogliomas. Unfortunately, management of glioblastoma is still mainly palliative. Incidence of primary CNS lymphoma has increased strikingly in the past 20 years; substantial progress has been achieved in patients who are immunocompetent with the addition of methotrexate-based chemotherapy to radiotherapy, but the potential neurotoxic effects of this combination in elderly patients is worrisome.

Entities:  

Mesh:

Year:  2003        PMID: 12559880     DOI: 10.1016/S0140-6736(03)12328-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  219 in total

1.  Opinion and evidence in neurology and psychiatry.

Authors: 
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

2.  Independent prognostic value of pre-treatment 18-FDG-PET in high-grade gliomas.

Authors:  Cécile Colavolpe; Philippe Metellus; Julien Mancini; Maryline Barrie; Céline Béquet-Boucard; Dominique Figarella-Branger; Olivier Mundler; Olivier Chinot; Eric Guedj
Journal:  J Neurooncol       Date:  2011-12-15       Impact factor: 4.130

3.  ¹⁸F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas.

Authors:  Kenji Hirata; Shunsuke Terasaka; Tohru Shiga; Naoya Hattori; Keiichi Magota; Hiroyuki Kobayashi; Shigeru Yamaguchi; Kiyohiro Houkin; Shinya Tanaka; Yuji Kuge; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02-04       Impact factor: 9.236

4.  Favorable long-term outcome of low-grade oligodendrogliomas irrespective of 1p/19q status when treated without radiotherapy.

Authors:  Yasuo Iwadate; Tomoo Matsutani; Yuzo Hasegawa; Natsuki Shinozaki; Yoshinori Higuchi; Naokatsu Saeki
Journal:  J Neurooncol       Date:  2010-08-19       Impact factor: 4.130

5.  Primary CNS T-cell Lymphomas: A Clinical, Morphologic, Immunophenotypic, and Molecular Analysis.

Authors:  Madhu P Menon; Alina Nicolae; Hillary Meeker; Mark Raffeld; Liqiang Xi; Armin G Jegalian; Douglas C Miller; Stefania Pittaluga; Elaine S Jaffe
Journal:  Am J Surg Pathol       Date:  2015-12       Impact factor: 6.394

6.  Antagonists of growth hormone-releasing hormone cross the blood-brain barrier: a potential applicability to treatment of brain tumors.

Authors:  Laura B Jaeger; William A Banks; Jozsef L Varga; Andrew V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-23       Impact factor: 11.205

7.  Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma.

Authors:  Graziella Filippini; Chiara Falcone; Amerigo Boiardi; Giovanni Broggi; Maria G Bruzzone; Dario Caldiroli; Rita Farina; Mariangela Farinotti; Laura Fariselli; Gaetano Finocchiaro; Sergio Giombini; Bianca Pollo; Mario Savoiardo; Carlo L Solero; Maria G Valsecchi
Journal:  Neuro Oncol       Date:  2007-11-09       Impact factor: 12.300

8.  Neoplasia and neoplasm-associated lesions in laboratory colonies of zebrafish emphasizing key influences of diet and aquaculture system design.

Authors:  Jan M Spitsbergen; Donald R Buhler; Tracy S Peterson
Journal:  ILAR J       Date:  2012

Review 9.  Stem cells and the origin and propagation of brain tumors.

Authors:  Brian A Emmenegger; Robert J Wechsler-Reya
Journal:  J Child Neurol       Date:  2008-10       Impact factor: 1.987

10.  Outcome of radiosurgery for recurrent malignant gliomas: assessment of treatment response using relative cerebral blood volume.

Authors:  Hong Rye Kim; Se-Hwan Kim; Jung-Il Lee; Ho Jun Seol; Do-Hyun Nam; Sung Tae Kim; Kwan Park; Jong Hyun Kim; Doo-Sik Kong
Journal:  J Neurooncol       Date:  2014-12-09       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.